RxDoctor Payments Data

Emily Paulk, MD

Internal Medicine · New Orleans, LANPI 1417369869

Payments from drug & device makers

$2,207in general payments, 2019–2025

Across 125 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$851
  • Novo Nordisk$231
  • Astellas Pharma US Inc$182
  • AstraZeneca$166
  • Boston Scientific$147
  • Exact Sciences$107
  • plus $523 from 10 others

What the payments were for

  • Food & beverage$2,11296%
  • Education$954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,207 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,573
Medicare patients
150
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$60,877
EliquisApixaban34$32,089
JanuviaSitagliptin Phosphate23$30,548
MounjaroTirzepatide20$21,081
EntrestoSacubitril/Valsartan14$19,227
Repatha SureclickEvolocumab15$13,350
FarxigaDapagliflozin Propanediol11$10,135
Metformin Hcl41$1,540
Atorvastatin Calcium188$1,396
Labetalol Hcl23$1,244
Rosuvastatin Calcium71$1,012
Omeprazole41$950
Albuterol Sulfate HfaAlbuterol Sulfate26$932
Pantoprazole Sodium86$858
Levothyroxine Sodium95$841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$231$60,87757 claims
PfizerEliquis$76$32,08934 claims
Lilly USA, LLCMounjaro$104$21,08120 claims
AstraZenecaFarxiga$166$10,13511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →